header logo image


Page 173«..1020..172173174175..180190..»

Axiom Presenting “Safety First: How Integrated Clinical Platforms Offer a Critical Advantage in Managing the Various Points to Control Safety” at…

June 8th, 2022 1:52 am

TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be presenting and exhibiting at Outsourcing in Clinical Trials: Medical Devices USA 2022, June 8-9 in Irvine, CA.

Go here to read the rest:
Axiom Presenting “Safety First: How Integrated Clinical Platforms Offer a Critical Advantage in Managing the Various Points to Control Safety” at...

Read More...

Inventiva joins the Euronext Tech Leaders segment

June 8th, 2022 1:52 am

Daix (France), Long Island City (New York, United States), June 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that it will join the Euronext Tech Leaders initiative, a new Euronext segment comprised of more than 100 high-growth and leading Tech companies across Europe.

View original post here:
Inventiva joins the Euronext Tech Leaders segment

Read More...

Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

June 8th, 2022 1:52 am

BOSTON and LOUISVILLE, Ky., June 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented additional data and analyses from its Phase 2 trial of FCR001 and other studies of its Facilitated Allo-HSCT Therapy platform at the 2022 American Transplant Congress (ATC).

Visit link:
Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

Read More...

Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

June 8th, 2022 1:52 am

Thursday, June 16th @ 10:30 a.m. ET Thursday, June 16th @ 10:30 a.m. ET

Excerpt from:
Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

Read More...

Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

June 8th, 2022 1:52 am

SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 43rd Annual Global Healthcare Conference at 4:00 p.m. PT on Tuesday, June 14, 2022. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

See more here:
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Read More...

Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

June 8th, 2022 1:52 am

SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14 at 10:40am PT.

Read more:
Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

Read More...

Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET

June 8th, 2022 1:52 am

SAN FRANCISCO, June 07, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. Eastern Time in New York City, NY.

Go here to read the rest:
Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET

Read More...

DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

June 8th, 2022 1:52 am

Montrouge, France, June 7, 2022

Read more here:
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

Read More...

Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic…

June 8th, 2022 1:52 am

FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Original post:
Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic...

Read More...

Orphazyme Announces Publication of 2021 Financial Results and Annual Report

June 8th, 2022 1:52 am

Orphazyme A/SCompany announcementNo. 30/2022                                                                        Annual reportwww.orphazyme.com Company Registration No. 32266355

Read the original:
Orphazyme Announces Publication of 2021 Financial Results and Annual Report

Read More...

Notice to convene Annual General Meeting

June 8th, 2022 1:52 am

Orphazyme A/SCompany announcementNo. 31/2022www.orphazyme.comCompany Registration No. 32266355

See the rest here:
Notice to convene Annual General Meeting

Read More...

European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma

June 8th, 2022 1:52 am

Basel, 8 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for the CD20xCD3 T-cell engaging bispecific antibody Lunsumio® (mosunetuzumab), for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies. Lunsumio is an off-the-shelf therapy that is readily available, so people do not have to wait to start treatment.

Read more here:
European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma

Read More...

Addressing the ‘Trust Factor’: South Carolina Researchers Tackle Health Disparities Using Genetics – Physician’s Weekly

June 8th, 2022 1:50 am

Quenton Tompkins family tree is deeply rooted in rural McCormick County, South Carolina.

His grandfather was a sharecropper in McCormick. His mother, who turns 88 this month, grew up as the youngest of 24 children. Branches of aunts, uncles, and cousins now stretch from Florida to Chicago.

And although 48-year-old Tompkins has heard plenty of stories, his family holds its secrets, too.

He didnt know until he was an adult that his grandfather died of leukemia. And hes still unsure if his fathers bout with prostate cancer runs in the family. Tompkins mother and her siblings have dealt with a range of health issues, including diabetes, heart attacks, and strokes, but he still doesnt know what killed his grandmother more than 70 years ago.

Those are questions I go through personally, said Tompkins, a lobbyist for the Medical University of South Carolina. Theres another side to knowing where you come from.

Twenty-two years ago, President Bill Clinton announced the completion of a draft version of the Human Genome Project, a breakthrough he described as the language in which God created life. He predicted that scientists, armed with genetic discoveries, would find cures for Alzheimers disease, cancer, Parkinsons disease, and diabetes in the coming years.

Clintons prediction, of course, hasnt yet come to pass. But researchers in Charleston are hopeful that a large genetics research project underway across South Carolina may help scientists address some of the states persistent health disparities, which disproportionately impact its Black residents and regularly rank among the nations worst.

The university health system intends to enroll 100,000 of South Carolinas 5 million residents in genetic testing over the next four years in hopes of better understanding how DNA influences health. Researchers also want to recruit participants who reflect the diversity of the states population.

Its an ambitious goal. With nearly 27% of South Carolina residents identifying as Black or African American, the MUSC genetics research project, called In Our DNA SC, would if successful accomplish something most other genetics research projects have failed to do. Historically, diverse participation in this type of research has been very low.

Theres a trust factor. Its plain and simple, said Tompkins, who is developing an outreach program for the project.

He referenced Henrietta Lacks, a Black woman in Baltimore whose cells were used without her or her familys knowledge for research purposes by doctors at Johns Hopkins University in the 1950s, and the Tuskegee syphilis study, conducted over nearly 40 years starting in the 1930s. Researchers deceived hundreds of Black men enrolled in the study, telling them they were being treated for syphilis when, in fact, they were left untreated, even after penicillin became widely available.

Those are still fresh in many peoples minds, Tompkins said. Weve come a long way from those stories it doesnt dismiss what happened but there are a lot more controls and oversight in place to ward those things off from happening again.

But its not only history feeding this distrust. Bias and racism evident in medicine today contribute to the problem.

Diversity in genetics research is so low that approximately 90% of participants in projects launched since the first sequencing of the human genome have been individuals of European descent or those who identify as white, said Dr. Shoa Clarke, a pediatric cardiologist and geneticist at Stanford University.

These numbers affect real-life health care. Clarke and others published research last year showing that a DNA-based tool used to assess a patients risk of developing high cholesterol works reliably well only when administered to those of Northern European descent. Thats because the tool was developed using information from genetic bio-banks largely made up of DNA from white people. And aside from a large DNA bank compiled by the Department of Veterans Affairs, this is generally the norm.

Human beings, regardless of race, are more than 99% genetically identical, but small variations and mutations passed down through generations can influence health outcomes in huge ways, Clarke explained.

Genetics is not the cause of health disparities, he said. But as we move toward using genetics in clinical settings, its very possible they could create new disparities.

In South Carolina, health disparities between Black and white patients are already acute, said Marvella Ford, a researcher at MUSCs Hollings Cancer Center in Charleston.

South Carolina compared to the rest of the country were usually in the bottom tier, Ford said. The prostate cancer mortality rate in South Carolina, for example, is 2 times higher for Black men than white men, she said.

When you look at most other chronic conditions, she said, you see the same thing.

She called the genetics project at MUSC a great opportunity to open the doors. Even so, the topic of recruiting Black research participants for genetics studies is complex.

Theres debate on how we should be doing this work, said Shawneequa Callier, an attorney and an associate professor of bioethics at George Washington University. Theres just so much diversity in Africa. Its the cradle of humanity.

Men and women transported to Charleston and other American port cities during the transatlantic slave trade came from a wide region of Africa mostly from West Central Africa, but in large numbers from regions farther north, too. Once in America, they were often separated and forced hundreds of miles apart. This explains why someone whose ancestors lived on one of South Carolinas barrier islands may have inherited different genetic variants than someone from a multigenerational Black family inland in McCormick County, just north of Augusta, Georgia.

Thats also why categorizing genetics research participants simply as Black or African American, without more context, may not yield particularly useful research insights, Callier said.

If you dont study the data and study it well, thats a real dereliction of ethical duty, Callier said.

Those who choose to participate in the MUSC project stand to benefit from it directly, its organizers said. After submitting a saliva sample, each participant will receive a report indicating if they have one or more of three genetic conditions that may put them at a higher risk for heart disease and certain cancers such as one of the BRCA mutations linked to breast cancer. If they test positive for one of these conditions, they will be connected at no cost to a genetics counselor, who can assist with information and treatment options related to a patients inherited risks. Participants will also learn where their ancestors likely lived.

The de-identified DNA data will then be used by researchers at MUSC, as well as those at Helix, a private California-based genomics company, which will process the saliva samples and extract the genetic information from each participants sample. Researchers at MUSC and Helix have indicated they hope to use the results to better figure out how DNA affects population health. Heather Woolwine, an MUSC spokesperson, said the project will cost $15 million, some of which will be paid to Helix. Hospital revenue will fund the research, she said.

Tompkins expects to receive a lot of questions about how it all will work. But hes used to questions. He said he encountered much of the same hesitancy when he helped set up MUSC covid testing and vaccine sites across the state. Many people regardless of race worried microchips or tracking technology had been embedded into the covid vaccines, he said.

Tompkins found that the key to persuading residents in rural parts of the state to consider the covid vaccine was to seek out invitations from trusted, local leaders, then set up events with them. South Carolinas covid vaccination rate remains lower than the national average, but Tompkins said some skeptics have been more receptive to MUSCs message because the hospital system has focused on building relationships with organizers outside Charleston. He hopes to use those relationships to spread word about the new genetics research project.

You have to build those relationships and find community champions that can help you open doors and gather people, he said. Then, its about letting them choose.

By Lauren SausserKaiser Health News is a nonprofit news service covering health issues. It is an editorially independent program of the Kaiser Family Foundation, which is not affiliated with Kaiser Permanente.

Read the original here:
Addressing the 'Trust Factor': South Carolina Researchers Tackle Health Disparities Using Genetics - Physician's Weekly

Read More...

Dumb luck, genetics? Why have some people never caught COVID-19? | Daily Sabah – Daily Sabah

June 8th, 2022 1:50 am

It has been more than two years since the start of the global COVID-19 pandemic. Throughout that time, for some people, the infections became more frequent and hit closer to home. Their friends contracted coronavirus, and sometimes their children, grandparents and most of their co-workers too. It seemed to be only a matter of time before they would contract the virus as well but their luck never ran out it seems as if some people have never been knowingly infected with COVID-19 in over two years even after the wave of infections caused by the highly transmissible omicron variant.

If you ask them the reason, you'll hear all sorts of suppositions. For example, regular long trips on the underground will build up your resistance by repeatedly exposing you to small viral loads.

"This hypothesis falls in the realm of speculation," says Dr. Ulf Dittmer, director of the Institute of Virology at Essen University Hospital in Germany.

Some people not previously infected attribute it to scrupulously following COVID-19 precautions. Others thank their lucky stars for not contracting the virus from a contact person who later tested positive or while they partied at a club. Still, others wonder if they had an asymptomatic infection that wasn't detected, for instance before testing was widely available. Or maybe they did have symptoms but tested negative because the sample was collected improperly or the timing was inopportune.

Scientific attempts at an explanation go deeper, but there's no single definitive answer as to why some people still haven't caught COVID-19. A combination of factors could be the reason.

"A number of hypotheses appear plausible," says Dr. Leif Erik Sander, director of the Department of Infectious Diseases and Respiratory Medicine at Charit University Hospital in Berlin.

First of all, it's important to bear in mind that a significant number of COVID-19 infections go largely or completely unnoticed. In a systematic review and meta-analysis published late last year in the Journal of the American Medical Association (JAMA) Network Open, the authors noted that about 40% of people with a confirmed COVID-19 diagnosis were asymptomatic at the time of the test. The finding was based on 95 international studies involving nearly 30 million people.

The frequency of testing obviously plays a role in detecting infections. If you're not tested regularly, there's a greater chance you won't become aware of a mild or asymptomatic infection.

And your genes can play a role too in whether or not you get COVID-19.

"There are people who, owing to genetic characteristics, can't easily be infected with malaria or HIV (the virus that causes AIDS), for instance. In certain gradations this will also be true of Sars-CoV-2," says Sander, adding that the genetic factors aren't completely understood, however.

As virologist Dittmer explains, human leukocyte antigens (HLA) molecules, which are encoded by a complex of genes, play an important part in the body's immune response to pathogens such as Sars-CoV-2. He adds that a person's blood group, too, not only influences disease severity but perhaps also susceptibility to infection with the virus.

The protection provided by vaccinations is probably often underestimated. Although levels of antibodies in your blood able to bind to and neutralize invading coronaviruses decline some time after injection with a vaccine, "protection nevertheless remains significant for months," Sander says. "That, too, reduces infections."

Immune responses to COVID-19 vaccines vary from person to person. "If the response is especially good, vaccination in combination with a previous infection with one of the four endemic common cold coronaviruses can also play a role," he suggests.

According to Dittmer, a particular subclass of antibodies has been found to provide especially good protection from a novel coronavirus infection. "Measuring them is complicated though, so for the time being no one will know whether they've got these antibodies or not," he says.

The fact that children who get COVID-19 tend to have either no or only mild symptoms is down to their generally having an innate immune response that's stronger than the immune response of adults, according to Sander. It's often "preactivated," so to say.

Another phenomenon worth mentioning is that for a few days after getting an infection, people are typically less susceptible to infection with another pathogen. "This is due in part to interferons, which are defensive proteins in mucous membranes that also reduce susceptibility to Sars-CoV-2 in the event of contact with it in that time window," Sander says.

He also notes that some people's immune system may rid their body of the virus very quickly: "In a Swedish study, researchers detected specific T-cells (a type of white blood cell that's part of the immune system) in people who didn't test positive after contact with infected household members a sign their immune system had indeed engaged Sars-CoV-2 even though an infection or antibodies against the virus weren't always detectable."

So what are we to conclude? If you think you've somehow managed to skirt a COVID-19 infection, you may already have one behind you. Or you may have benefited from certain temporary circumstances, as-yet-unexplained genetic factors and/or dumb luck.

"Just because you haven't had COVID-19 yet doesn't mean you're permanently safe," Sander warns. "A new coronavirus variant, or a different set of circumstances, can totally change that."

The Daily Sabah Newsletter

Keep up to date with whats happening in Turkey, its region and the world.

SIGN ME UP

You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Read the rest here:
Dumb luck, genetics? Why have some people never caught COVID-19? | Daily Sabah - Daily Sabah

Read More...

Genetics Breakthrough in Sea Urchins to Aid in Biomedical Research – Scripps Institution of Oceanography

June 8th, 2022 1:50 am

Marine biologists at Scripps Institution of Oceanography at UC San Diego have created a line of sea urchins whose genetic makeup is fully mapped and can be edited to study human disease genes. The creation of these new research model organisms will accelerate the pace of marine biomedical research.

Sea urchins, like fruit flies or lab rats, have been an organism used in research for more than a century. Even before this breakthrough, sea urchins led to the discovery of a protein family known as cyclins that guides division of cells. That knowledge went on to become the basis of current cancer treatments and earned cyclins discoverers a Nobel Prize.

Now Scripps marine biologist Amro Hamdoun and colleagues have taken this research to a new level by developing lines of sea urchins that can be used as genetic models using the gene editing technology known as CRISPR. The modified sea urchins are derived from the fast-growing species, Lytechinus pictus, also known as the painted sea urchin.

The team describes its results June 6 in the journal Development.

Hamdoun said the new sea urchins could serve as a new workhorse organism in marine biomedical research, capable of being cultivated to adulthood in four to six months at room temperature. Presently many species of sea urchins are used around the world to study the developmental origins of diseases, and the effects of pollutants on human and marine health. But few can be grown in the lab and genetically modified like other lab animals. Having this new genetically enabled urchin could dramatically enhance the efficiency, reproducibility, and utility of those studies.

Sea urchins have long been a favorite model organism for marine biologists, but they have been bottlenecked by not having stable genetics, Hamdoun said. This work breaks that final barrier. This genetically enabled urchin will be an important resource for the large community of researchers who use urchins in their labs.

The research was an unexpected silver lining from the COVID pandemic which impacted operations in research labs around the country for more than two years. In the case of Hamdouns lab, team members developed a sense of mission that motivated them to continue with the work.

It gave us something positive to focus on, Hamdoun said. The team spent two years intently focused on solving the barriers to making a genetically enabled sea urchin. Once we figured out how to make the precise modifications we wanted, we next had to figure out how to efficiently culture the urchins and select the modified animals. It is a real testament to the groups dedication that they accomplished this despite the adverse circumstances. I like to think that while many people were home growing cool things like houseplants or sourdough starters, we were also growing something interesting, but it was a biomedical research animal.

Besides Hamdoun, co-authors of the study included Himanshu Vyas, Jose Espinoza, Catherine Schrankel, Kasey Mitchell, Katherine Nesbit, Elliot Jackson, Nathan Chang, Yoon Lee, and Deirdre Lyons of Scripps Oceanography as well as researchers from University of North Carolina Charlotte and Wilmington campuses.

The National Institutes of Health Program on Oceans and Human Health and the National Science Foundation funded the research.

Read more:
Genetics Breakthrough in Sea Urchins to Aid in Biomedical Research - Scripps Institution of Oceanography

Read More...

Bazelet to Supply Its Federally Legal Cannabis Genetics to DEA Approved Research Entities for Rigorous Scientific Research on the Clinical Effects of…

June 8th, 2022 1:50 am

COLUMBIA, Md., June 07, 2022 (GLOBE NEWSWIRE) -- Neon Bloom, Inc. (OTC: NBCO): Bazelet Health Systems, a wholly owned subsidiary of Neon Bloom, is proud to announce the endowment of a program known as cERI (cannabis Education & Research Initiative). The program encompasses the donation by Bazelet of federally legal cannabis genetics (genetically producing 0% THC) to DEA registered research entities, such as the National Center for the Development of Natural Products at the University of Mississippi and the broader qualified scientific community wishing to conduct, disseminate and support rigorous scientific research on the clinical effects of cannabis. The companys genetics are patented, compliant with the Controlled Substances Act (CSA) and are now available to all to conduct research with our genetics.

Global scientific research of the Cannabis Sativa L. plant has been illegal because of the Controlled Substance Act (CSA). The CSA has created a decades-long pent-up demand for the scientific research of the cannabis plant by qualified research entities. In 2016, the DEAannouncedthat it was amending its longstanding policies to allow additional parties to grow cannabis for clinical research purposes. Since that time, it amended its regulations in 2020 (which became effective in January 2021) to facilitate the cultivation of marihuana for research purposes and other licit purposes to enhance compliance with the Controlled Substances Act, including registering cultivators consistent with treaty obligations but has not legalized cannabis research. In fact, to date, the DEA has only acknowledged providing a MOA (Memorandum of Agreement) to just a handful of applicants to work together to facilitate the production, storage, packaging, and distribution of marijuana. (www.dea.gov). Meanwhile, human health and the global scientific community standby helpless, until now. Our genetic library of non-GMO, patented Cannabis Sativa L. plants offers access to cannabinoids such as Cannabigerol (CBG) with no existing THC or CBD, said Dr. Francisco Ward, NBPAS-PM&R/PM, Chief Medical Officer for Bazelet which makes us a prime candidate for research endeavors.

Having been involved with the DEA regarding its amendment to facilitate the cultivation of marihuana for research purposes and other licit purposes to enhance compliance with the Controlled Substances Act, I recognize and appreciate the DEAs unique implementation challenges. I am certain our patented cannabis plants and robust plant science program can immediately deliver value to their program, their researchers, and manufacturers. For decades worldwide, cannabis plants have been almost exclusively bred to yield higher and higher concentrations of Tetrahydrocannabinol (THC) which has fueled a multi-billion recreational and high THC medical marijuana industry. This breeding habit has caused the abandonment, if you will, of hundreds of compounds in the cannabis plant to the detriment of human health, scientific study, and federal law. We have developed an unprecedented plant genetic platform for the DEA that begins with registered, US plant patent approved, Cannabis Sativa L. plants as its foundation. Our unique genetic program will allow DEA registered research entities to unlock untold scientific and human health outcomes by accessing a full array of cannabinoids and compounds found in the Cannabis Sativa L. plant, such as Cannabigerol (CBG). Our program allows the DEA from here forward, the development of world-class cannabis genetics that began with registered, US patented cannabis genetics, says Michael Elzufon, CEO of the Bazelet Health Systems.

Through our cannabis Education & Research Initiative (cERI), we are opening our genetic library to DEA registered research entities, encouraging their rigorous scientific and medical research projects with federally legal cannabis products. With the DEA slow in issuing bulk manufacturer registrations, research projects remain on hold and our patented, federally compliant cannabis genetics are an immediate solution, said Dr. Ward. He added, I look forward to collaborating with colleagues, scientists, DEA bulk manufacturer applicants and patients everywhere, to study, innovate and access the potential of this plant in the areas of neurodegenerative diseases, auto-immune diseases, vascular diseases, psychiatric diseases such as addiction, delusional states, and PTSD.

About Neon Bloom: Neon Bloom, Inc. (OTC: NBCO), doing business as Bazelet Health Systems, Inc. ("Bazelet"), holds the exclusive license to grow in the United States a patented zero-THC, high CBG Cannabis sativa L plant which received United States Patent No. PP32,725 on January 5, 2021. The patented plant, which was named PAN2020, is remarkably high in Cannabigerol (CBG) with undetectable levels (zero percent) of both Cannabidiol (CBD) and Tetrahydrocannabinol (THC). Consistent with the company's mantra to create zero-THC products (the company's Cannabis-ZERO platform), Bazelet is actively developing non-GMO cannabis Sativa plants that produce zero-THC while being rich in CBG and other valuable cannabinoids. Bazelet is a wholly owned subsidiary of the public company that manufactures and markets PECSA, a patent-pending, proprietary full extract of the PAN2020 plant with other added proprietary ingredients. PECSA stands for Plant-based EndoCannabinoid System Activator. The EndoCannabinoid System is the premier regulatory center of the body affecting mental abilities, emotions, pain, inflammation, ne and metabolic functions with receptors found primarily in the brain and immune cells. The company's primary focus is to sell and market PECSA as a non-GMO, plant-based ingredient for the global food, drug, cosmetic, and tobacco industries. To meet the anticipated worldwide demand for PECSA, Bazelet has established a vertically integrated supply chain providing operational control from patented cannabis plants to proprietary patented plant processing to GMP-produced finished products, all with traceability from seed to sale. Bazelet grows patented plants in North America, Europe, South America, and the Middle East coming online in 2023. Processing and distribution facilities are located in the U.S. and Europe.

Disclaimer:This Press Release is for informational purposes, contains forward-looking statements based on current expectations, forecasts, and assumptions with information available to us as of the date hereof, and involves risks and uncertainties. This Press Release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Actual results may differ materially from those implied in forward-looking statements. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "would" or similar words. We assume no obligation to update the information included in this Press Release, whether from new information, future events, or otherwise.

CONTACT: Dr. Mat BlantonEMAIL: media@bazelethealth.comWEBSITE: http://www.bazelethealth.com

Go here to read the rest:
Bazelet to Supply Its Federally Legal Cannabis Genetics to DEA Approved Research Entities for Rigorous Scientific Research on the Clinical Effects of...

Read More...

Genetic Control Of Autoimmune Disease Mapped To Cellular Level – Bio-IT World

June 8th, 2022 1:50 am

June 8, 2022 | The pioneering OneK1K study in Australia has identified an immune fingerprint of seven autoimmune disorders using single-cell RNA sequencing (scRNA-seq). The general framework, which combines the scRNA-seq data with genotype data to classify individual cells, can be applied to many different diseases, including other autoimmune disorders, cardiovascular diseases, neuroinflammatory conditions, and cancer where the immune system is thought to play a role, according to Joseph Powell, director of cellular science at the Garvan Institute of Medical Research.

Selection of the original seven diseasesmultiple sclerosis, rheumatoid arthritis, lupus, type 1 diabetes, spondylitis, inflammatory bowel disease, and Crohns diseasewere based on their prevalence in the world of autoimmune diseases and high genetic component, he says. The study relied on scRNA-seq data from 1.27 million peripheral blood mononuclear cells collected from 982 healthy donors, many of whom carry the genetic loci found in people who have these diseases.

Take Crohns disease, which has molecular markers found on roughly 190 positions in the genome, Powell cites as an example. On average, patients collectively have roughly 90 risk alleles at those loci, but individually about 60. It is the difference between having 60 and 90 that takes you over the threshold and leads to occurrences of disease.

This phenomenon holds true for most every disease afflicting humans, which is why a big population group is ideal for gaining mechanistic insights on disease-associated genes, he continues. At the cellular level, genome regulation changes brought on by those genes are the same even if there is no clinical manifestation of disease.

Using a Mendelian randomization approach, Powell and his colleagues uncovered the causal route by which 305 loci contribute to autoimmune disease through changes in gene expression in specific cell types and subsetsand that these genetic mechanisms are the same for healthy individuals as in autoimmune disease cohorts. Results published recently in Science (DOI: 10.1126/science.abf30).

Single-cell RNA sequencing was used to look at genetic variants affecting gene expression in 14 different immune cell types, says Powell. It is the largest study to date linking disease-causing genes to specific types of immune cells.

Researchers developed a classification method based on the transcriptomic signature found in individual cells and aligned it back to what is currently understood about more common immune cell types at the top of the hierarchy (e.g., T cells, CD4, CD8, nave to memory B cells). Although 68 immune cells have been classified, they focused on those they were sure to find enough copies of across the OneK1K cohort to confidently link the genetic differences between people to the signatures in the cells.

Tissue-To-Tissue Variability

Powell says he has been interested in genetic control of gene expression, and its contribution to disease, for more than a decade now. For many years, this involved bulk RNA analysis that produces an average signal.

An important clue emerged when researchers began seeing how vastly different the genetics worked in one tissue versus another, he says. Only a few years ago, the Genotype-Tissue Expression Program (GTEx) of the National Institutes of Health examined RNA sequencing samples from 49 tissues of postmortem donors to characterize genetic associations for gene expression and found regulatory associations for almost all genes. Cell type composition was identified as a key factor in understanding gene regulatory mechanisms.

That study showed instances where genetic effects were seen in one tissue and not another, or generated completely different effects, Powell notes. It was published in 2020 when scRNA-sequencing was just emerging as a staple technologyand Powell had just started his computational genomics laboratory at the Garvan Institute.

We were stuck with this interesting question: If we see these differences between tissues, and know the tissues are comprised of really distinct cell types with really specific functional roles, and the transcriptomic cell signatures are different, can we try to create a system to undo the genetics we saw in tissue inside a cell? That led Powell and his colleagues to scale up their scRNA-sequencing efforts.

At the time, the vast amount of generated transcript data generated from 1,000 individuals would have made scRNA-sequence data entirely cost-prohibitive to generate. But Powell helped pioneer a biometric technique to pool cells from multiple samples, as well as a method to analyze the transcripts of individual cells that solved the challenge of determining what portion of them would provide the most useful information in defining a cell type.

Up until then, a few other groups had published studies using samples from perhaps 50 or 100 individuals suggesting signatures of disease, but they were all under-powered, says Powell. They could show genetic differences between cells, but they were all too under-powered to link them to disease, or to resolve why there were differences between cells.

Statistically speaking, disease fingerprints that capture the genetic heterogeneity of patients will never be fully defined, says Powell. But the OneK1K study has probably moved the needle from the 10th percentile to the 50th percentile on the saturation curve.

Powell is now aiming for the 95th percentile with a TenK10K study that will be seeking to enroll 10,000 individuals and generate single cell data on about 50 million cells. The multi-year initiative will involve partnerships with multiple hospitals across Australia, and both a healthy population group and patients newly diagnosed with autoimmune disorders, cardiovascular disease, and cancer.

Autoimmune diseases affect about one in 12 Australians, he notes. They are incurable and require lifelong treatments to minimize the damage. Patients often try many different treatments before finding one that works for them.

The genetic mechanisms are actually really generic, he says. You can learn a lot by linking what we see in [OneK1K study] data to what already know just about genetic positions in disease. Now, were taking those genetic positions from genome-wide association studies and will show mechanisms of action and specifically the cell types they are acting in.

Pure fundamental science is a major driver for the work, says Powell, knowledge creation for human disease... and making all the data publicly available. Since the Science paper published in April, he has been fielding multiple data requests daily.

The more translational outcome is the possibility that the catalogue of genetic mechanisms will be useful in predicting which treatments will work best for individual patients, Powell says. To test that hypothesis, Powells lab is in the process of conducting a series of retrospective and prospective signal-seeking studies using currently marketed drugsstarting with immunotherapy treatment of cancer.

If successful, patients will one day be able to get a very cheap test costing literally tens of dollars [in Australia anyway] to guide the clinical decision-making of their treating physician, Powell says. We think that across a population we will be able to move the efficacy of a drug from, say, 30%which is pretty common for immunotherapy and a lot of inhibitory drugs in autoimmune diseaseto 50% or 60%. Even a 10-percentile gain for a single drug would be remarkable in terms of patient impact, he adds.

Along the way, the molecular mechanisms of disease are being unearthed at the cellular RNA level and that data could be shared with pharmaceutical companies to inform their early-stage drug development work, including which targets to take forward to phase 1 clinical trials, says Powell. Already, four pharma companies and one biotech have approached him about just such partnering opportunity, which would additionally aid them in the selection of patient groups for treatment trials.

Scientific strides have been a team effort by many committed individuals, he says, crediting the 16 co-authors on the latest study hailing from Sydney, Hobart, Melbourne, Brisbane, and San Francisco. They consider themselves part of the larger, decade-long movement toward open science, marked by transparency, open communication, and access to the data and computer code used to reach conclusions.

See the original post:
Genetic Control Of Autoimmune Disease Mapped To Cellular Level - Bio-IT World

Read More...

Alameda County Awaits Key Decision Regarding The Use of Genetic Testing in Asbestos Cases – JD Supra

June 8th, 2022 1:50 am

Alameda County Superior Court Judge Jo-Lynne Q. Lee set a hearing on nationally recognized plaintiffs firm Maune Raichle French Hartley & Mudd. LLCs motion for protective order in a pending asbestos case in which the defendants experts wanted to perform genetic testing. The case is John Lohmann and Suzanne Lohmann v. Aaon, Inc., et al. Alameda County Superior Court Case No. RG21098862. In this case, the plaintiffs filed their action in May 2021 in Alameda County against several defendants alleging that Mr. Lohmann contracted mesothelioma occupationally during his career as a refrigeration equipment mechanic beginning in the early 1970s largely in California.

After appearing in the action, the defendants retained pathology experts who wanted to use Mr. Lohmanns medical data for non-litigation purposes without Mr. Lohmanns permission, because the experts believed that the information would advance science. To conduct this testing, counsel for designated defense counsel moved for discovery of Mr. Lohmanns original cytology/pathology slides and paraffin blocks and subpoenaed his health care providers. The court ordered production of those original materials. According to the plaintiffs counsel, production of Mr. Lohmanns pathology and genetic material during litigation does not thereby permit outside, personal research and analysis. Multiple defendants disagreed, however, and contend that evidence produced during litigation enters the public domain and is thereafter not protected by discovery law.

As a result, on January 7, 2022 the plaintiffs filed for a protective order under California Code of Civil Procedure 2025.420, arguing that they never discussed with defense counsel the terms by which Mr. Lohmanns pathology material was to be used. The plaintiffs asked Alameda County Superior Court to block defendants from compiling medical data for the benefit of a third partys medical database or research project. Defendants, in their written opposition and during oral argument, contend that there is no authority barring medical research on data derived during litigation. Defendants also contend that the plaintiffs are incorrectly relying on Californias discovery statutes, which only govern how the evidence is obtained, not how it can be used. Defendants also argue that research evidence derived from litigation is relevant not only for diagnosis, treatment, and cause, but also helps determine the plaintiffs damages. For example, the defendants cite to scientific research showing that patients with the BAP-1 mesothelioma marker respond better to treatment and tend to have longer life expectancies than those patients without this marker. Defendants wish to present this evidence to the jury as they decide Mr. Lohmanns claim for future medical costs and damages for shortened life expectancy.

Up until last year, defendants and the plaintiffs in Alameda County operated under an informal discovery agreement regarding a plaintiffs pathology materials. However, with more and more defense experts looking to see if a plaintiff, like Mr. Lohmann, had the BAP-1 mesothelioma marker, the Maune firm revoked this informal agreement citing privacy and concerns over genetic testing of their clients materials. Their concerns were largely centered on the actions of longtime defense pathology expert, Dr. Victor Roggli, who published an article in 2020 describing an individual previously represented by the Maune firm.[1] According to the Maune firm, Dr. Rogglis use of their clients medical data in his non-litigation research was improper. In regard to the testing for BAP-1 in particular, the plaintiffs in Lohmann are attempting to block it arguing that it has questionable value in a mesothelioma case. The plaintiffs imply in their motion that the defendants are hoping to use published research linking BAP-1 mutations and certain asbestos exposures in litigation.

It is now up to Alameda County Superior Court to decide whether these defendants and the Dr. Rogglis of the world can, legally under the Discovery Act, use a plaintiffs medical data for their own non-litigation purposes without first obtaining the plaintiffs permission. The Court has requested additional briefing from the parties on this subject before it will make this determination. Defendants are urging the Court to retain an independent expert to examine this issue.

For the Lohmann case, the hearing on the plaintiffs protective order did not go forward after the Defendants stipulated that none of their experts intended to use any of Mr. Lohmanns medical information outside of litigation.

So, for now at least, this issue has been tabled until the next case. But, if and when Alameda County does make a ruling on this issue, its decision will have a significant impact on genetic defenses for mesothelioma cases in California and, likely, elsewhere in the nation as well. The courts eventual opinion will decide whether asbestos defendants can use a plaintiffs medical data in third-party research that could potentially help gather information useful to defendants defenses to damages claims in future asbestos cases.

[1] Mujahed T, Tazelaar HD, Sukov WR, Halling KC, Davila JI, Glass C, Pavlisko EN, Strickland KC, Roggli V, Haque M, Mneimneh W, Carter E, Galateau-Salle F, Glidden D, Garcia-Kennedy R, Larsen BT. Malignant Peritoneal Mesothelioma Arising in Young Adults With Long-standing Indwelling Intra-abdominal Shunt Catheters. Am J Surg Pathol. 2021 Feb 1;45(2):255-262. doi: 10.1097/PAS.0000000000001574. PMID: 32826527.

Original post:
Alameda County Awaits Key Decision Regarding The Use of Genetic Testing in Asbestos Cases - JD Supra

Read More...

Diversity in Genetic Research Is Key to Enhancing Treatment of Chronic Diseases in Africa – Technology Networks

June 8th, 2022 1:50 am

The lack of diversity in genomic research could mean Africans are missing out on potential life-changing care for chronic health disorders, according to a new study published inNature Medicine.

Genetic risk scores are a tool used to estimate an individuals risk of developing a disease, based on genetic factors. Researchers are able to find out someones genetic risk score by examining a populations genetic data and linking genetic factors to various health outcomes to indicate how likely they are to experience certain conditions.

These genetic risk scores are thought to revolutionise medicine by making it possible for people to receive treatments in line with their genetic make up, as well as for early identification and prevention of diseases. However, due to the small numbers of genetic studies involving African people, there is not currently enough information to create accurate genetic risk scores to predict their vulnerability to illnesses such as heart diseases.

The study, led by researchers from theMRC/UVRI and the London School of Hygiene & Tropical Medicine (LSHTM) Uganda Research Unit in collaboration with those from the University of Witwatersrand in South Africa, used genetic data from 1.4 million people of diverse ancestry across sub-Saharan Africa to examine how the use of diverse and representative data can impact our ability to predict disease risk.

The team found that when genetic data from the African American population was included in genomic studies, the genetic risk score estimates were five times more accurate for people with African ancestry, compared to when data from European ancestry was used.

African Americans only comprise 1.1% of global genomic studies. These findings emphasise the importance of including Africans genetic information in genomic studies in order to gain more accurate information about genetic risk factors for disease, and better control the growing trend of chronic health disorders in Africa.

Segun Fatumo, Associate Professor of Genetic Epidemiology & Bioinformaticsat theMRC/UVRI and LSHTM Uganda Research Unit said: "Currently, genomic studies include primarily individuals with European ancestry. This means genetic risk scores in predicting risk of disease, while applicable to the European population, is not accurate or reliable for those of African ancestry. It is crucial that we address this lack of diversity in genomic data. More genomic research is required to produce genetic risk scores that are relevant and representative of the genetic diversity in African populations due to age, lifestyle, environment, and other genetic factors."

Researchers used data from Uganda and South Africa to gather genetic information using genetic risk scores to identify people within continental African populations with high and low fat levels. Their findings identified a number of inherent features in African populations, including that the genetic risk scores were more accurate for people living in urban settings in South Africa than for those in Uganda, due to differences in age, lifestyles, environments and genetics.

Additionally, by including well-known risk factors, such as age, gender, body mass index (BMI) and type 2 diabetes in the estimation of genetic risk scores, the classification of people with either high or low risks improved by 42%.

This was in contrast to conventional risk factors reported in European-based studies such as age, gender, and body mass index as significant contributors to identifying people with high and low fat levels. These findings also demonstrate that a standard genetic risk score cannot be applied across different ethnicities and nations in Africa due to genetic variability and other factors which affect risk such as age, lifestyle and environment.

The team also divided the population into three categories to indicate whether they have a low, medium or high risk of developing a disease. This could help clinicians and genetic specialists to evaluate an individuals risk of disease, especially those at high risk of developing chronic diseases.

Early diagnosis and treatment is one of the best ways to reduce the chances of developing chronic diseases such as heart and blood vessel disorders. The lack of diversity in genetic studies, and those that include African people in particular, has slowed progress in calculating individuals susceptibility to illnesses, which in turn slows their path to diagnosis and treatment.

Although genetic risk scores are not extensively used by health professionals at the moment, the researchers believe these findings provide hope for enhancing clinical care in Africa. Knowing how likely an individual is to get a disease could help them take preventative steps to diagnose it earlier, when it is easier to treat, or even cure. According to the researchers, this is crucial for detecting those who are at risk of having high levels of body fat in the future.

Dr. Tinashe Chikowore, from the University of the Witwatersrand and an author of this study, said: "Advocating for greater diversity in genetic studies will guarantee that Africa is not left out of future precision medicine initiatives, which are crucial in identifying people who are more or less susceptible to contract chronic infections."

Reference:KamizaAB, Toure SM, Vujkovic M, et al. Transferability of genetic risk scores in African populations. Nat Med. 2022. doi: 10.1038/s41591-022-01835-x

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the original post:
Diversity in Genetic Research Is Key to Enhancing Treatment of Chronic Diseases in Africa - Technology Networks

Read More...

CSU partners with American Hereford Association on genetics research – Beef Magazine

June 8th, 2022 1:50 am

Colorado State University researchers are partnering with the American Hereford Association to support cattle producers and the beef industry in finding sustainable solutions to environmental and economic challenges.

The new research aims to enhance understanding of genetic differences in seedstock relative to enteric methane production and nitrogen excretion while identifying selection tools that can help reduce beef's carbon and environmental footprint.

"We're excited to begin this cooperative research agreement with Colorado State University,"says Jack Ward, executive vice president of the American Hereford Association, one of the largest beef breed associations in the United States. "It leverages decades of research and data collected by AHA members aimed at characterizing genetics associated with production efficiency, which plays a key role in environmental and economic sustainability."

Environmental and economic challengesDirect emissions from the animal agriculture sector account for 3.8% of U.S. greenhouse gas emissions, according to the Environmental Protection Agency. Enteric methane accounts for approximately 27% of methane emissions in the U.S.

Methane emission, as a genetic trait in cattle, appears to be moderately heritable with genetic correlations to economically relevant production traits, such as measures of growth, dry matter intake and various estimates of feed efficiency.

Worldwide attention is also focusing more intently on nitrogen a byproduct of rumen fermentation. Previous research suggests genetics play a significant role in nitrogen excretion by cattle, and when selected for, an individual animal's environmental footprint can be reduced.

"We know genetic improvement of our industry is driven by gains made in the seedstock sector. One only needs to look at changes in carcass meat yield and quality over the last two decades to realize the potential for improvements in seedstock genetics to transform the entire beef industry,"says Animal Sciences Professor Mark Enns, a beef cattle geneticist and key member of the research team.

Sustainable solutions"Often, we hear criticism leveled at the beef industry regarding greenhouse gas emissions and the impact of cattle on the environment, but with little context,"Enns says. "Cattle also sequester carbon and contribute to environmental health. This project will contribute to the beef cattle industry's goal of demonstrating carbon neutrality by 2040."

Given the Hereford breed's inherent genetic advantages associated with production efficiency, Ward says documenting the relationship between traits associated with efficiency and greenhouse gas emissions is logical next step for the breed and the industry.

"Beef industry stakeholders including the National Cattlemen's Beef Association have committed to improving the environmental impact of U.S. cattle production. This project aims to develop a selection tool for the American Hereford Association and the broader cattle industry that helps producers identify genetics that will have reduced greenhouse gas emissions without sacrificing animal productivity,"says Kim Stackhouse-Lawson, director of CSU AgNext, a pioneering research collaborative developing sustainable solutions for animal agriculture.

By leveraging existing animal performance data and monitoring animal emissions, Stackhouse-Lawson explains the goal is to identify genetic traits that influence environmental emissions from individual animals and then develop selection indices that can be used to reduce the environmental impact of cattle, while maintaining, and ideally improving economic returns to producers.

"This project will also position the American Hereford Association as a sustainability leader in the beef industry through the development of genetic selection tools that can identify and inform breeders of genetics that meet climate goals without sacrificing quality, performanceand efficiency," says Stackhouse-Lawson.

Further, Enns notes the project has potential to pave new paths of revenue for cattle producers. These could include such things as verified sustainable production claims, in addition to commonly discussed carbon credits.

Supporting the beef industryThe U.S. beef cattle industry has a long history of demonstrating extraordinary gains in efficiency over time, using genetics, technology and management to produce more beef with fewer cows and less land.

"This research will help us identify ways to magnify the gains the industry has already achieved," Ward says.

"CSU is involved in this project because we are passionate about beef production and the beef industry, and the societal benefits it brings from the upcycling of human-inedible plant materials and byproducts into high-quality protein,"Enns says. "From a genetic improvement standpoint, CSU has a long history of new trait development and delivery of selection tools to the industry. As such, we feel we have much to contribute in this realm, striving to produce cattle that meet consumer demands, yet have a smaller environmental footprint."

Source: Colorado State University, whichis solely responsible for the information provided, and wholly owns the information. Informa Business Media and all its subsidiaries are not responsiblefor any of the contentcontained in this information asset.

Follow this link:
CSU partners with American Hereford Association on genetics research - Beef Magazine

Read More...

Page 173«..1020..172173174175..180190..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick